Allergoid Immunotherapy Product
Clustek Max is a next-generation European-developed allergoid subcutaneous immunotherapy (SCIT) product that builds on the Clustek platform by offering enhanced flexibility for combining multiple allergens while maintaining the safety advantages of an allergoid formulation. This makes it particularly suitable for patients sensitised to several environmental allergens such as dust mites, grasses, and pollens.
Overview
Clustek Max is administered exclusively in a clinic by trained specialists under controlled protocols and is designed to support personalised immunotherapy plans tailored to patient needs.
Safety Profile
Clustek Max maintains the reduced risk of systemic reactions characteristic of allergoids. Common side effects include:
Common side effects include:
Mild local swelling or redness at the injection site
Temporary itching or discomfort
Rare systemic reactions, managed with standard emergency procedures in the clinic
Effectiveness
Clustek Max has demonstrated efficacy in improving symptoms and reducing the reliance on allergy medications.
Clinical benefits typically emerge over months, with long-term improvement expected over a 3–5 year course. The flexible multi-allergen formulation may offer advantages for patients with complex allergy profiles.
3–5 year treatment course
Treatment options
Single allergen therapy
Single allergen therapy:
While capable of single-allergen use, Clustek Max is optimised for patients requiring multi-allergen treatment.
Multi-allergen therapy
Multi-allergen therapy:
The primary advantage of Clustek Max is the ability to combine multiple allergens safely within a single preparation, streamlining treatment for patients with polysensitisation.
Both TGA-registered and non-registered options exist.
Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.
Administered via subcutaneous injection in clinic
Initial build-up phase with gradual dose increases
Maintenance phase involves less frequent injections for sustained desensitisation
Requires patient monitoring for potential adverse reactions
Patient Suitability
Clustek may be appropriate for patients who:
Are polysensitised to multiple environmental allergens
Require an allergoid approach due to sensitivity
Seek a flexible, clinic-supervised immunotherapy plan
Are able to attend regular clinic visits for SCIT administration
Australian Context
Not PBS-subsidised; treatment is privately funded
Conclusion
Clustek Max provides a premium, flexible, and safe allergoid SCIT solution for patients with multiple environmental allergies. Its enhanced multi-allergen capability supports personalised treatment plans, balancing safety and potential clinical benefit.
Clustek Max is particularly well-suited for patients requiring controlled desensitisation across several allergens.
